Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Mirati Therapeutics (MRTX)

Mirati Therapeutics (MRTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,273,424
  • Shares Outstanding, K 43,642
  • Annual Sales, $ 3,340 K
  • Annual Income, $ -213,260 K
  • 60-Month Beta 1.83
  • Price/Sales 1,315.02
  • Price/Cash Flow N/A
  • Price/Book 6.66

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -2.10
  • Number of Estimates 7
  • High Estimate -1.92
  • Low Estimate -2.25
  • Prior Year -1.26
  • Growth Rate Est. (year over year) -66.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
90.25 +3.50%
on 05/05/20
116.86 -20.07%
on 05/12/20
+2.04 (+2.23%)
since 05/04/20
3-Month
66.01 +41.51%
on 03/18/20
116.86 -20.07%
on 05/12/20
-2.47 (-2.58%)
since 03/04/20
52-Week
66.01 +41.51%
on 03/18/20
132.59 -29.55%
on 01/02/20
-4.62 (-4.71%)
since 06/04/19

Most Recent Stories

More News
Mirati Therapeut Set to Possibly Rebound After Yesterday's Selloff of 2.00%

Mirati Therapeut (NASDAQ:MRTX) traded in a range yesterday that spanned from a low of $96.37 to a high of $99.60. Yesterday, the shares fell 2.0%, which took the trading range below the 3-day low of...

MRTX : 93.41 (-4.61%)
Shares of MRTX Up 18.6% Since Uptrend Call on Shares

SmarTrend identified an Uptrend for Mirati Therapeut (NASDAQ:MRTX) on March 25th, 2020 at $82.01. In approximately 2 months, Mirati Therapeut has returned 18.62% as of today's recent price of $97.28.

MRTX : 93.41 (-4.61%)
After Yesterday's Decline of 1.10%, Mirati Therapeut Offers Investors Better Value

Mirati Therapeut (NASDAQ:MRTX) traded in a range yesterday that spanned from a low of $97.79 to a high of $101.17. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of...

MRTX : 93.41 (-4.61%)
Mirati Therapeutics Appoints Joseph A. Leveque, M.D. As Chief Medical Officer

, /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that , M.D. has been named Chief Medical Officer effective . , M.D., will step...

MRTX : 93.41 (-4.61%)
Mirati Therapeutics To Present Preclinical Data From Investigational Pipeline Of Novel Therapeutics At 2020 American Association For Cancer Research Virtual Annual Meeting II

, /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced it will present preclinical data on the Company's pipeline of novel therapeutics...

MRTX : 93.41 (-4.61%)
SmarTrend Watching for Potential Pullback in Shares of Mirati Therapeut After 7.96% Gain

Mirati Therapeut (NASDAQ:MRTX) traded in a range yesterday that spanned from a low of $106.13 to a high of $114.48. Yesterday, the shares gained 8.0%, which took the trading range above the 3-day high...

MRTX : 93.41 (-4.61%)
Mirati (MRTX) Reports Q1 Loss, Lags Revenue Estimates

Mirati (MRTX) delivered earnings and revenue surprises of -22.42% and -58.92%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

MRTX : 93.41 (-4.61%)
Mirati: 1Q Earnings Snapshot

SAN DIEGO (AP) _ Mirati Therapeutics Inc. (MRTX) on Thursday reported a loss of $86.7 million in its first quarter.

MRTX : 93.41 (-4.61%)
Mirati Therapeutics Reports First Quarter 2020 Financial Results And Recent Corporate Updates

, /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results and a corporate update for the first quarter ended .

MRTX : 93.41 (-4.61%)
Shares of MRTX Up 9.9% Since Uptrend Call on Shares

SmarTrend identified an Uptrend for Mirati Therapeut (NASDAQ:MRTX) on March 25th, 2020 at $82.01. In approximately 1 month, Mirati Therapeut has returned 9.86% as of today's recent price of $90.09.

MRTX : 93.41 (-4.61%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade MRTX with:

Business Summary

Mirati Therapeutics, Inc. is a biopharmaceutical company. It engaged in the development of novel therapeutics for the treatment of cancer. Mirati Therapeutics, Inc., formerly known as MethylGene Inc., is based in Montreal, Canada.

See More

Key Turning Points

2nd Resistance Point 101.18
1st Resistance Point 97.29
Last Price 93.41
1st Support Level 91.27
2nd Support Level 89.14

See More

52-Week High 132.59
Fibonacci 61.8% 107.16
Fibonacci 50% 99.30
Last Price 93.41
Fibonacci 38.2% 91.44
52-Week Low 66.01

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar